Report copyright - Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, … · Mol Cancer Ther; 10(12); 2298–308. 2011 AACR. Introduction The receptor tyrosine kinase MET is the only known receptor
Please pass captcha verification before submit form